Marshall Wace, LLP Autolus Therapeutics PLC Transaction History

Marshall Wace, LLP

$77.3 Billion
Q3 2024

A detailed history of Marshall Wace, LLP transactions in Autolus Therapeutics PLC stock. As of the latest transaction made, Marshall Wace, LLP holds 757,535 shares of AUTL stock, worth $1.63 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

757,535

Previous 757,535 -0.0%

Holding current value

$1.63 Million

Previous $2.64 Million 4.29%

% of portfolio

0.0%

Previous 0.0%

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$3.33 - $5.68 $939,532 - $1.6 Million	-282,142 Reduced 27.14%	757,535 $2.64 Million
Q1 2024 May 15, 2024	BUY	$5.39 - $7.29 $2.93 Million - $3.96 Million	542,724 Added 109.21%	1,039,677 $6.63 Million
Q4 2023 Feb 14, 2024	BUY	$2.13 - $6.63 $1.06 Million - $3.29 Million	496,953 New	496,953 $3.2 Million
Q2 2023 Aug 14, 2023	BUY	$1.64 - $3.21 $41,813 - $81,842	25,496 New	25,496 $60,000
Q1 2022 May 16, 2022	SELL	$3.52 - $5.46 $56,946 - $88,331	-16,178 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$5.1 - $7.0 $1.44 Million - $1.97 Million	-281,571 Reduced 94.57%	16,178 $85,000
Q2 2021 Aug 13, 2021	BUY	$4.78 - $7.96 $949,958 - $1.58 Million	198,736 Added 200.72%	297,749 $1.98 Million
Q1 2021 May 17, 2021	BUY	$5.49 - $9.36 $543,581 - $926,761	99,013 New	99,013 $568,000
Q3 2020 Nov 16, 2020	SELL	$11.64 - $16.3 $159,142 - $222,853	-13,672 Closed	0 $0
Q2 2020 Aug 13, 2020	SELL	$5.38 - $16.14 $2.54 Million - $7.61 Million	-471,557 Reduced 97.18%	13,672 $220,000
Q1 2020 May 15, 2020	SELL	$4.2 - $13.0 $818,798 - $2.53 Million	-194,952 Reduced 28.66%	485,229 $2.91 Million
Q4 2019 Feb 14, 2020	BUY	$11.13 - $16.28 $1.93 Million - $2.82 Million	173,174 Added 34.16%	680,181 $8.98 Million
Q3 2019 Nov 14, 2019	SELL	$9.79 - $16.72 $82,216 - $140,414	-8,398 Reduced 1.63%	507,007 $6.3 Million
Q2 2019 Aug 14, 2019	BUY	$15.1 - $31.25 $4.27 Million - $8.83 Million	282,474 Added 121.27%	515,405 $8.3 Million
Q1 2019 May 14, 2019	BUY	$24.38 - $34.71 $2.74 Million - $3.9 Million	112,489 Added 93.4%	232,931 $7.33 Million
Q4 2018 Feb 14, 2019	BUY	$24.21 - $48.01 $2.92 Million - $5.78 Million	120,442 New	120,442 $3.96 Million

Others Institutions Holding AUTL

# of Institutions

108

Shares Held

163M

Call Options Held

2.8K

Put Options Held

13.4K

View Full List

About Autolus Therapeutics plc

Ticker AUTL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 90,909,800
Market Cap $195M
Description
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which...

More about AUTL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Marshall Wace, LLP with notifications on news.

Account

Marshall Wace, LLP Autolus Therapeutics PLC Transaction History